. 2023 May 19;8:204. doi: 10.1038/s41392-023-01468-7

Table 2.

Four licensed JAKis for RA treatment

JAKis	Main trials	T_1/2	Excretion	Clinically used doses	ref.
Baricitinib	Phase III, Genovese et al. (RA-BEACON); Phase III, Dougados et al. (RA-BUILD); Phase III, Fleischmann et al. (RA-BEGIN); and Phase III, Taylor et al. (RA-BEAM)	9–13 h	Urine75%, and Stool20%	2 mg/4 mg	^475–478
Tofacitinib	ORAL program: Phase III, Fleischmann et al. (ORAL solo); Phase III, Burmester et al. (ORAL step); Phase III, Vollenhoven et al. (ORAL-standard); Phase III, Kremer et al. (ORAL sync); Phase III, van der Heijde et al. (ORAL scan); and Phase III, Lee et al. (ORAL start)	3 h	Urine51%, and Stool13%	5 mg/10 mg	^200–205
Filgotinib	Phase III, Genovese et al,(FINCH 2 trial), and Extension Study of Phase II, Kavanaugh et al. (DARWIN 3)	6 h	Urine87%, and Stool15%	100 mg/200 mg	^{177,178,196,197}
Upadacitinib	Phase III, Cohenet et al. (SELECT program)	8–14 h	Urine24%, and Stool38%	15 mg/30 mg	^{261,262,265,266}